Pharma Capital

Clinigen boss happy with contribution from all divisions in latest half year

Shaun Chilton, chief executive at Clinigen Group PLC (LON:CLIN), told Proactive he was very happy with the firm's latest half year.
The specialty pharma group confirmed that underlying profits [adjusted EBITDA] rose 34% to £30mln in the half year to end December on revenues of £131mln (£156mln)
"I think it's a strong performance and particularly because every single business division contributed," he told Andrew Scott.

 

View full CLIN profile

Clinigen Group PLC Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.